Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing)

June 2013 | 173 pages | ID: P31D0B4F535EN
Renub Research

Abstracts

Personalized Medicine Diagnostics - Market Overview

Personalized Medicine is often defined as “the right treatment for the right person at the right time.” Personalized medicine is becoming the place to be in clinical diagnostics as well and slowly becoming the reality of future in the diagnostics industry

By Technology Segment - Personalized Medicine diagnostics market is expected to grow with a double digit CAGR for the period of 2013 to 2018. It is expected that personalized medicine diagnostics market by technology is going to double by 2018 from its current market size in 2012. In this segment, Point of Care Testing and Molecular Diagnostics segments control the #1 and #2 positions in 2012.

By Diseases Segment - Personalized Medicine diagnostics market is expected to be more than US$ 30 Billion by 2018. Diabetes management test and Cancer management test are the leading market in this segment.

Renub Research report entitled “Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing)” report provides a comprehensive analysis of the emerging personalized medicine diagnostic market segments, including their dynamics, size, market share, key investors, clinical trials statement, technological trends, company analysis and a realistic future potential for personalized medicine in clinical testing. The report also entails major drivers and challenges of personalized medicine diagnostic market. This 173 page report contains 94 Figures and 16 Tables studies the Personalized Medicine Diagnostics Market. This report contains 12 chapters

• Chapter 1 is Executive Summary
• Chapter 2 contains worldwide personalized medicine diagnostic market & forecast (2011 – 2018). The market includes technological & disease-wise personalized medicine diagnostics market
• Chapter 3 contains worldwide personalized medicine diagnostic market share segment. Segment include Technology, Disease-Wise
• Chapter 4 contains segment-wise technological personalized diagnostic market & forecast (2010 - 2018)
• Chapter 5 contains geographical segment-wise personalized diagnostic market & forecast (2011 - 2018)
• Chapter 6 contains disease-wise personalized diagnostic market share & forecast (2011 - 2018)
• Chapter 7 contains disease-wise personalized diagnostic market & forecast (2011 - 2018)
• Chapter 8 and 9 contains clinical trial statement and key investors in Personalized Diagnostics Medicine Market
• Chapter 10 and 11 contains growth Drivers & Challenges for Personalized Medicine
• Chapter 12 contains company analysis of Personalized Medicine

Companies analyzed in this report are:

• HistoRx
• A&G Pharmaceuticals Inc
• 20/20 GeneSystems
• Tethys Bioscience
• Genomas Inc

Data Sources

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.

Primary sources include industry surveys and telephone interviews with industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Contents

1. EXECUTIVE SUMMARY

2. WORLDWIDE PERSONALIZED MEDICINE DIAGNOSTIC MARKET & FORECAST

2.1 By Technology – Worldwide Personalized Medicine Diagnostic Market & Forecast
2.2 By Diseases – Worldwide Personalized Medicine Diagnostic Market & Forecast

3. WORLDWIDE – PERSONALIZED MEDICINE DIAGNOSTIC MARKET SHARE SEGMENT

3.1 By Technology – Worldwide Personalized Medicine Diagnostic Market Share & Forecast
3.2 By Disease – Worldwide Personalized Medicine Diagnostic Market Share & Forecast

4. BY TECHNOLOGY – PERSONALIZED MEDICINE DIAGNOSTIC MARKET & FORECAST

4.1 Worldwide – Pharmacogenetics Market & Forecast
4.2 Worldwide – Pharmacogenomics Market & Forecast
4.3 Worldwide – SNP Genotyping Market & Forecast
4.4 Worldwide – Pharmacoproteomics Market & Forecast
4.5 Worldwide – Biochips Market & Forecast
4.6 Worldwide – Point of Care Test Market & Forecast
4.7 Worldwide – Molecular Diagnostics Market & Forecast
4.8 Worldwide – Genetic Screening Market & Forecast

5. BY GEOGRAPHICAL SEGMENTATION – PERSONALIZED MEDICINE DIAGNOSTIC MARKET & FORECAST

5.1 North America – Personalized Medicine Diagnostic Market & Forecast
5.2 Western Europe (EU5) – Personalized Medicine Diagnostic Market & Forecast

6. BY DISEASE – PERSONALIZED MEDICINE DIAGNOSTIC MARKET SHARE & FORECAST

6.1 Worldwide – Cardiovascular Management Test Market Share & Forecast
6.2 Worldwide – Diabetes Management Test Market Share & Forecast
6.3 Worldwide – Coagulation Test Market Share & Forecast
6.4 Worldwide – Cancer Management Test Market Share & Forecast
6.5 Worldwide – Infectious Diseases Test Market Share & Forecast

7. BY DISEASE – PERSONALIZED MEDICINE DIAGNOSTIC MARKET & FORECAST

7.1 Worldwide – Cardiovascular Management Test Market & Forecast
7.2 Worldwide – Cardiovascular Management Test Market & Forecast (By Segment)
  7.2.1 Cardiac Marker Immunoassays Market & Forecast
  7.2.2 Cardiac Risk Markers Market & Forecast
  7.2.3 Cardiac Markers Molecular Test Market & Forecast
7.3 Worldwide – Diabetes Management Test Market & Forecast
7.4 Worldwide – Diabetes Management Test Market & Forecast (By Segment)
  7.4.1 Blood Glucose Monitoring Market & Forecast
  7.4.2 Hemoglobin A1C (HbA1c) Test Market & Forecast
7.5 Worldwide – Coagulation Test Market & Forecast
7.6 Worldwide – Coagulation Test Market & Forecast (By Segment)
  7.6.1 Routine Coagulation Test Market & Forecast
  7.6.2 Molecular Coagulation Test Market & Forecast
7.7 Worldwide – Cancer Management Test Market & Forecast
7.8 Worldwide – Cancer Management Test Market & Forecast (By Segment)
  7.8.1 Pharmacodiagnostic Histology Test Market & Forecast
  7.8.2 Flow Cytometry Market & Forecast
  7.8.3 Tumor Markers Market & Forecast
  7.8.4 Human Papillomavirus (HPV) Test Market & Forecast
  7.8.5 Molecular Assays Market & Forecast
  7.8.6 Circulating Tumor Cells Market & Forecast
7.9 Worldwide – Infectious Diseases Test Market & Forecast
7.10 Worldwide – Infectious Diseases Test Market (By Segment)
  7.10.1 Human Immunodeficiency Virus (HIV) CD4 Count Market & Forecast
  7.10.2 Human Immunodeficiency Virus (HIV) Viral Load Test Market & Forecast
  7.10.3 Hepatitis C (HCV) Viral Load Test Market & Forecast
  7.10.4 Hepatitis B (HBV) Viral Load Test Market & Forecast
  7.10.5 Hospital Acquired Infections (HAI) Molecular Test Market & Forecast
  7.10.6 Sepsis Immunos Test Market & Forecast
  7.10.7 Multi Drug Resistant Tuberculosis (MDR-TB) Test Market & Forecast
7.11 Worldwide – Microbiology Identification/ Antibiotic Sensitivity Test (ID/AST) Market & Forecast
7.12 Worldwide – Psychiatric Disorders Test Market & Forecast
7.13 Worldwide – Transplant Tissue Typing (HLA) Test Market & Forecast
7.14 Worldwide – Molecular Blood Typing Market & Forecast

8. PERSONALIZED MEDICINE CLINICAL TRIAL STATEMENT

8.1 Biomarker Research for Personalized Medicine in Blood Cancer Patient
8.2 Genetic & Environmental Determinants of Immune Phenotype Variance: Establishing a Path towards Personalized Medicine
8.3 Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation (WARFARIN)
8.4 Genetic Analysis for Personalized Medicine for Morbid Obesity
8.5 Pharmacogenomics for Antidepressant Guidance & Education
8.6 I-SPY 2 Trial (Investigation of Serial Studies to Predict your Therapeutic Response with Imaging & Molecular Analysis)
8.7 Genetic Mechanisms in Human Hypertension RAAS Inhibition Study
8.8 Open Label Study for the Functional Characterization of Drug Metabolism and Transport
8.9 Personalized Therapy in Non-Small Cell Lung Cancer
8.10 A Pilot Study of Personalized Medicine for Pediatric Asthma

9. KEY INVESTORS IN PERSONALIZED MEDICINE MARKET

10. KEY DRIVERS (OPPORTUNITIES) OF GROWTH IN PERSONALIZED MEDICINE DIAGNOSTIC MARKET

10.1 Government Agencies Shaping Personalized Medicine Diagnostic Market
10.2 Organizations will Profit Together, Not Alone in the Personalized Medicine
10.3 The Blockbuster Model of One Drug Fits all is under Pressure

11. CHALLENGES IN PERSONALIZED MEDICINE DIAGNOSTIC MARKET

11.1 Reimbursement Policy & Regulatory Framework
11.2 Regulatory Framework
11.3 Payers Worry That Cost of Personalized Medicine Could Be Unsustainable

12. COMPANY ANALYSIS

12.1 HistoRx
  12.1.1 Focus/Market Served
  12.1.2 Outlook/ Strategy for Success
  12.1.3 Products
12.2 A&G Pharmaceutical, Inc
  12.2.1 Focus/Market Served
  12.2.2 Outlook/Strategy for Success
  12.2.3 Products
12.3 20/20 GeneSystems
  12.3.1 Focus/Market Served
  12.3.2 Outlook/Strategy for Success
  12.3.3 Products
12.4 Tethys Bioscience
  12.4.1 Focus/Market Served
  12.4.2 Outlook/Strategy for Success
  12.4.3 Products
12.5 Genomas, Inc.
  12.5.1 Focus/Market Served
  12.5.2 Products

List Of Figures

LIST OF FIGURES:

Figure 2 1: Worldwide – By Technology Personalized Medicine Diagnostic Market (Million US$), 2010 – 2012
Figure 2 2: Worldwide – Forecast for By Technology Personalized Medicine Diagnostic Market (Million US$), 2013 – 2018
Figure 2 3: Worldwide – By Diseases Personalized Medicine Diagnostic Market (Million US$), 2011 – 2012
Figure 2 4: Worldwide – Forecast for By Diseases Personalized Medicine Diagnostic Market (Million US$), 2013 – 2018
Figure 3 1: Worldwide – By Technology Personalized Medicine Diagnostic Market Share (Percent), 2010 – 2012
Figure 3 2: Worldwide – Forecast for By Technology Personalized Medicine Diagnostic Market Share (Percent), 2013 – 2018
Figure 4 1: Worldwide – Pharmacogenetics Market (Million US$), 2010 – 2012
Figure 4 2: Worldwide – Forecast for Pharmacogenetics Market (Million US$), 2013 – 2018
Figure 4 3: Worldwide – Pharmacogenomics Market (Million US$), 2010 – 2012
Figure 4 4: Worldwide – Forecast for Pharmacogenomics Market (Million US$), 2013 – 2018
Figure 4 5: Worldwide – SNP Genotyping Market (Million US$), 2010 – 2012
Figure 4 6: Worldwide – Forecast for SNP Genotyping Market (Million US$), 2013 – 2018
Figure 4 7: Worldwide – Pharmacoproteomics Market (Million US$), 2010 – 2012
Figure 4 8: Worldwide – Forecast for Pharmacoproteomics Market (Million US$), 2013 – 2018
Figure 4 9: Worldwide – Biochips Market (Million US$), 2010 – 2012
Figure 4 10: Worldwide – Forecast for Biochips Market (Million US$), 2013 – 2018
Figure 4 11: Worldwide – Point of Care Testing Market (Million US$), 2009 – 2012
Figure 4 12: Worldwide – Forecast for Point of Care Testing Market (Million US$), 2013 – 2018
Figure 4 13: Worldwide – Molecular Diagnostics Market (Million US$), 2010 – 2012
Figure 4 14: Worldwide – Forecast for Molecular Diagnostics Market (Million US$), 2013 – 2018
Figure 4 15: Worldwide – Genetic Screening Market (Million US$), 2010 – 2012
Figure 4 16: Worldwide – Forecast for Genetic Screening Market (Million US$), 2013 – 2018
Figure 5 1: North America – Personalized Medicine Diagnostic Market (Million US$), 2011 – 2012
Figure 5 2: North America – Forecast for Personalized Medicine Diagnostic Market (Million US$), 2013 – 2018
Figure 5 3: Western Europe (EU-5) – Personalized Medicine Diagnostic Market (Million US$), 2011 – 2012
Figure 5 4: Western Europe (EU-5) – Forecast for Personalized Medicine Diagnostic Market (Million US$), 2013 – 2018
Figure 6 1: Worldwide – Cardiovascular Management Test Market Share (Percent), 2011 – 2012
Figure 6 2: Worldwide – Forecast for Cardiovascular Management Test Market Share (Percent), 2013 – 2018
Figure 6 3: Worldwide – Diabetes Management Test Market Share (Percent), 2011 – 2012
Figure 6 4: Worldwide – Forecast for Diabetes Management Test Market Share (Percent), 2013 – 2018
Figure 6 5: Worldwide – Coagulation Test Market Share (Percent), 2011 – 2012
Figure 6 6: Worldwide – Forecast for Coagulation Test Market Share (Percent), 2013 – 2018
Figure 6 7: Worldwide – Cancer Management Test Market Share (Percent), 2011 – 2012
Figure 6 8: Worldwide – Forecast for Cancer Management Test Market Share (Percent), 2013 – 2018
Figure 6 9: Worldwide – Infectious Diseases Test Market Share (Percent), 2011 – 2012
Figure 6 10: Worldwide – Forecast for Infectious Diseases Test Market Share (Percent), 2013 – 2018
Figure 7 1: Worldwide – Cardiovascular Management Test Market (Million US$), 2011 – 2012
Figure 7 2: Worldwide – Forecast for Cardiovascular Management Test Market (Million US$), 2013 – 2018
Figure 7 3: Worldwide – Cardiac Marker Immunoassays Market (Million US$), 2011 – 2012
Figure 7 4: Worldwide – Forecast for Cardiac Marker Immunoassays Market (Million US$), 2013 – 2018
Figure 7 5: Worldwide – Cardiac Risk Markers Market (Million US$), 2011 – 2012
Figure 7 6: Worldwide – Forecast for Cardiac Risk Markers Market (Million US$), 2013 – 2018
Figure 7 7: Worldwide – Cardiac Markers Molecular Test Market (Million US$), 2011 – 2012
Figure 7 8: Worldwide – Forecast for Cardiac Markers Molecular Test Market (Million US$), 2013 – 2018
Figure 7 9: Worldwide – Diabetes Management Test Market (Million US$), 2011 – 2012
Figure 7 10: Worldwide – Forecast for Diabetes Management Test Market (Million US$), 2013 – 2018
Figure 7 11: Worldwide – Blood Glucose Monitoring Market (Million US$), 2011 – 2012
Figure 7 12: Worldwide – Forecast for Blood Glucose Monitoring Market (Million US$), 2013 – 2018
Figure 7 13: Worldwide – Hemoglobin A1C (HbA1c) Test Market (Million US$), 2011 – 2012
Figure 7 14: Worldwide – Forecast for Hemoglobin A1C (HbA1c) Test Market (Million US$), 2013 – 2018
Figure 7 15: Worldwide – Coagulation Test Market (Million US$), 2011 – 2012
Figure 7 16: Worldwide – Forecast for Coagulation Test Market (Million US$), 2013 – 2018
Figure 7 17: Worldwide – Routine Coagulation Test Market (Million US$), 2011 – 2012
Figure 7 18: Worldwide – Forecast for Routine Coagulation Test Market (Million US$), 2013 – 2018
Figure 7 19: Worldwide – Molecular Coagulation Test Market (Million US$), 2011 – 2012
Figure 7 20: Worldwide – Forecast for Molecular Coagulation Test Market (Million US$), 2013 – 2018
Figure 7 21: Worldwide – Cancer Management Test Market (Million US$), 2011 – 2012
Figure 7 22: Worldwide – Forecast for Cancer Management Test Market (Million US$), 2013 – 2018
Figure 7 23: Worldwide – Pharmacognostic Histology Test Market (Million US$), 2011 – 2012
Figure 7 24: Worldwide – Forecast for Pharmacognostic Histology Test Market (Million US$), 2013 – 2018
Figure 7 25: Worldwide – Flow Cytometry Market (Million US$), 2011 – 2012
Figure 7 26: Worldwide – Forecast for Flow Cytometry Market (Million US$), 2013 – 2018
Figure 7 27: Worldwide – Tumor Markers Market (Million US$), 2011 – 2012
Figure 7 28: Worldwide – Forecast for Tumor Markers Market (Million US$), 2013 – 2018
Figure 7 29: Worldwide – Human Papillomavirus (HPV) Test Market (Million US$), 2011 – 2012
Figure 7 30: Worldwide – Forecast for Human Papillomavirus (HPV) Test Market (Million US$), 2013 – 2018
Figure 7 31: Worldwide – Molecular Assays Market (Million US$), 2011 – 2012
Figure 7 32: Worldwide – Forecast for Molecular Assays Market (Million US$), 2013 – 2018
Figure 7 33: Worldwide – Circulating Tumor Cells Market (Million US$), 2011 – 2012
Figure 7 34: Worldwide – Forecast for Circulating Tumor Cells Market (Million US$), 2013 – 2018
Figure 7 35: Worldwide – Infectious Diseases Test Market (Million US$), 2011 – 2012
Figure 7 36: Worldwide – Forecast for Infectious Diseases Test Market (Million US$), 2013 – 2018
Figure 7 37: Worldwide – HIV CD4 Count Market (Million US$), 2011 – 2012
Figure 7 38: Worldwide – Forecast for HIV CD4 Count Market (Million US$), 2013 – 2018
Figure 7 39: Worldwide – HIV Viral Load Test Market (Million US$), 2011 – 2012
Figure 7 40: Worldwide – Forecast for HIV Viral Load Test Market (Million US$), 2013 – 2018
Figure 7 41: Worldwide – HCV Viral Load Test Market (Million US$), 2011 – 2012
Figure 7 42: Worldwide – Forecast for HCV Viral Load Test Market (Million US$), 2013 – 2018
Figure 7 43: Worldwide – HBV Viral Load Test Market (Million US$), 2011 – 2012
Figure 7 44: Worldwide – Forecast for HBV Viral Load Test Market (Million US$), 2013 – 2018
Figure 7 45: Worldwide – HAI Molecular Test Market (Million US$), 2011 – 2012
Figure 7 46: Worldwide – Forecast for HAI Molecular Test Market (Million US$), 2013 – 2018
Figure 7 47: Worldwide – Sepsis Immunos Test Market (Million US$), 2011 – 2012
Figure 7 48: Worldwide – Forecast for Sepsis Immunos Test Market (Million US$), 2013 – 2018
Figure 7 49: Worldwide – Multi Drug Resistant Tuberculosis (MDR-TB) Market (Million US$), 2011 – 2012
Figure 7 50: Worldwide – Forecast for Multi Drug Resistant Tuberculosis (MDR-TB) Market (Million US$), 2013 – 2018
Figure 7 51: Worldwide – Microbiology ID/AST Market (Million US$), 2011 – 2012
Figure 7 52: Worldwide – Forecast for Microbiology ID/AST Market (Million US$), 2013 – 2018
Figure 7 53: Worldwide – Psychiatric Disorders Test Market (Million US$), 2011 – 2012
Figure 7 54: Worldwide – Forecast for Psychiatric Disorders Test Market (Million US$), 2013 – 2018
Figure 7 55: Worldwide – Transplant Tissue Typing (HLA) Test Market (Million US$), 2011 – 2012
Figure 7 56: Worldwide – Forecast for Transplant Tissue Typing (HLA) Test Market (Million US$), 2013 – 2018
Figure 7 57: Worldwide – Molecular Blood Typing Market (Million US$), 2011 – 2012
Figure 7 58: Worldwide – Forecast for Molecular Blood Typing Market (Million US$), 2013 – 2018

List Of Tables

LIST OF TABLES

Table 3 1: Worldwide – By Diseases Personalized Medicine Diagnostic Market Share (Percent), 2011 – 2012
Table 3 2: Worldwide – Forecast for By Diseases Personalized Medicine Diagnostic Market Share (Percent), 2013 – 2018
Table 7 1: Selected Human Papillomavirus (HPV) Tests, 2011
Table 7 2: Selected Molecular Personalized Medicine Tests in Cancer, 2011
Table 8 1: Clinical Trial – Biomarker Research for Personalized Medicine in Blood Cancer Patient
Table 8 2: Clinical Trial – Genetic & Environmental Determinants of Immune Phenotype Variance: Establishing a Path Towards Personalized Medicine
Table 8 3: Clinical Trial – Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation
Table 8 4: Clinical Trial – Genetic Analysis for Personalized Medicine for Morbid Obesity
Table 8 5: Clinical Trial – Pharmacogenomics for Antidepressant Guidance & Education
Table 8 6: Clinical Trial – I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging & molecular Analysis)
Table 8 7: Clinical Trial – Genetic Mechanisms in Human Hypertension RAAS Inhibition Study
Table 8 8: Clinical Trial – Open Label Study for the Functional Characterization of Drug Metabolism and Transport
Table 8 9: Clinical Trial – Personalized Therapy in Non-small Cell Lung Cancer
Table 8 10: Clinical Trial – A Pilot Study of Personalized Medicine for Pediatric Asthma
Table 9 1: Key Investors in Personalized Medicine, 2011 & 2012
Table 12 1: Partnership & Alliance Models in Personalized Medicine